Kalivir Immunotherapeutics
Permanently closed
240 Alpha Dr
Pittsburgh, PA 15238
Kalivir designs safe and potent oncolytic product candidates across multiple tumor types. Kalivir's cutting-edge, next generation oncolytic viral immunotherapy programs combine technologies developed in-house and licensed from University of Pittsburgh's world-class oncolytic virus and immunotherapy research programs.
Also at this address
See a problem?
You might also like
Partial Data by Infogroup (c) 2025. All rights reserved.